REVANCE THERAPEUTICS INC (RVNC)
US7613301099 - Common Stock
RVNC gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. RVNC may be in some trouble as it scores bad on both profitability and health. RVNC is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year RVNC has reported negative net income.
RVNC had a negative operating cash flow in the past year.
RVNC had negative earnings in each of the past 5 years.
RVNC had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -39.96%, RVNC is in line with its industry, outperforming 45.55% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -39.96% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-60.64%
ROA(5y)-53.59%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
RVNC has a Gross Margin of 72.61%. This is in the better half of the industry: RVNC outperforms 79.58% of its industry peers.
RVNC's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for RVNC so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 72.61% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.51%
GM growth 5YN/A
2. Health
2.1 Basic Checks
RVNC does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, RVNC has more shares outstanding
Compared to 5 years ago, RVNC has more shares outstanding
The debt/assets ratio for RVNC is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -6.39, we must say that RVNC is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -6.39, RVNC is not doing good in the industry: 65.97% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -6.39 |
ROIC/WACCN/A
WACC8.1%
2.3 Liquidity
A Current Ratio of 4.12 indicates that RVNC has no problem at all paying its short term obligations.
The Current ratio of RVNC (4.12) is better than 60.21% of its industry peers.
RVNC has a Quick Ratio of 3.05. This indicates that RVNC is financially healthy and has no problem in meeting its short term obligations.
RVNC has a Quick ratio (3.05) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.12 | ||
| Quick Ratio | 3.05 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 53.16% over the past year.
RVNC shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 15.34%.
RVNC shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 129.20% yearly.
EPS 1Y (TTM)53.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.3%
Revenue 1Y (TTM)15.34%
Revenue growth 3Y148.24%
Revenue growth 5Y129.2%
Sales Q2Q%5.47%
3.2 Future
The Earnings Per Share is expected to grow by 17.92% on average over the next years. This is quite good.
The Revenue is expected to grow by 23.66% on average over the next years. This is a very strong growth
EPS Next Y57.03%
EPS Next 2Y30.61%
EPS Next 3Y22.8%
EPS Next 5Y17.92%
Revenue Next Year12.8%
Revenue Next 2Y19.79%
Revenue Next 3Y22.43%
Revenue Next 5Y23.66%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
RVNC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RVNC. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
RVNC's earnings are expected to grow with 22.80% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.61%
EPS Next 3Y22.8%
5. Dividend
5.1 Amount
RVNC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
REVANCE THERAPEUTICS INC
NASDAQ:RVNC (12/20/2024, 8:00:01 PM)
After market: 3.05 -0.04 (-1.29%)3.09
+0.02 (+0.65%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners72.87%
Inst Owner Change-0.78%
Ins Owners1.85%
Ins Owner Change-0.07%
Market Cap322.57M
Analysts70
Price Target9.13 (195.47%)
Short Float %13.24%
Short Ratio4.72
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)19.02%
Min EPS beat(2)4.62%
Max EPS beat(2)33.41%
EPS beat(4)4
Avg EPS beat(4)19.57%
Min EPS beat(4)4.62%
Max EPS beat(4)33.41%
EPS beat(8)5
Avg EPS beat(8)-1.49%
EPS beat(12)6
Avg EPS beat(12)-3.54%
EPS beat(16)10
Avg EPS beat(16)-1.96%
Revenue beat(2)0
Avg Revenue beat(2)-8.84%
Min Revenue beat(2)-14.73%
Max Revenue beat(2)-2.96%
Revenue beat(4)1
Avg Revenue beat(4)-4.4%
Min Revenue beat(4)-14.73%
Max Revenue beat(4)10.16%
Revenue beat(8)3
Avg Revenue beat(8)-2.2%
Revenue beat(12)6
Avg Revenue beat(12)-0.84%
Revenue beat(16)9
Avg Revenue beat(16)2.98%
PT rev (1m)0%
PT rev (3m)-4.02%
EPS NQ rev (1m)0%
EPS NQ rev (3m)19.51%
EPS NY rev (1m)-13.24%
EPS NY rev (3m)-13.24%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-16.39%
Revenue NY rev (1m)-7.54%
Revenue NY rev (3m)-7.33%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1.31 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.93
EYN/A
EPS(NY)-1.11
Fwd EYN/A
FCF(TTM)-1.87
FCFYN/A
OCF(TTM)-1.83
OCFYN/A
SpS2.37
BVpS-1.56
TBVpS-1.63
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -39.96% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 72.61% | ||
| FCFM | N/A |
ROA(3y)-60.64%
ROA(5y)-53.59%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.51%
GM growth 5YN/A
F-Score3
Asset Turnover0.54
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 106.69% | ||
| Cap/Sales | 1.63% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.12 | ||
| Quick Ratio | 3.05 | ||
| Altman-Z | -6.39 |
F-Score3
WACC8.1%
ROIC/WACCN/A
Cap/Depr(3y)40.78%
Cap/Depr(5y)54.97%
Cap/Sales(3y)6.23%
Cap/Sales(5y)171.26%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)53.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.3%
EPS Next Y57.03%
EPS Next 2Y30.61%
EPS Next 3Y22.8%
EPS Next 5Y17.92%
Revenue 1Y (TTM)15.34%
Revenue growth 3Y148.24%
Revenue growth 5Y129.2%
Sales Q2Q%5.47%
Revenue Next Year12.8%
Revenue Next 2Y19.79%
Revenue Next 3Y22.43%
Revenue Next 5Y23.66%
EBIT growth 1Y31.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year82.08%
EBIT Next 3Y29.15%
EBIT Next 5Y20.68%
FCF growth 1Y9.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y8.22%
OCF growth 3YN/A
OCF growth 5YN/A